Compare PRHI & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRHI | SCNX |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Other Pharmaceuticals |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7M | 16.2M |
| IPO Year | 2015 | 2019 |
| Metric | PRHI | SCNX |
|---|---|---|
| Price | $7.26 | $2.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.2K | ★ 42.6K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $43,304,000.00 | $3,831,778.00 |
| Revenue This Year | N/A | $1,009.57 |
| Revenue Next Year | N/A | $259.51 |
| P/E Ratio | $4.39 | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $0.59 | $2.81 |
| 52 Week High | $11.34 | $106.25 |
| Indicator | PRHI | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 46.61 |
| Support Level | $4.05 | N/A |
| Resistance Level | $7.95 | $11.68 |
| Average True Range (ATR) | 0.80 | 8.40 |
| MACD | -0.10 | -0.85 |
| Stochastic Oscillator | 28.05 | 0.04 |
Presurance Holdings Inc is an insurance holding company that markets and services product offerings through specialty personal insurance lines of business. Through its personal insurance lines, it offers homeowners insurance and dwelling fire insurance products to individuals in several states. The specialty homeowners insurance product line is comprised of low-value dwelling insurance tailored for owners of lower valued homes, which it offers in Texas, Illinois and Indiana. Through commercial insurance lines, it offers coverage for both commercial property and commercial liability and also offered coverage for commercial automobiles and workers' compensation. Its revenues are derived from premiums earned from insurance operations.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.